Loading clinical trials...

Carotid Artery Intima-Media Thickness Following Exposure to Raloxifene or Placebo | Clinical Trials | Clareo Health

COMPLETEDPHASE4

Carotid Artery Intima-Media Thickness Following Exposure to Raloxifene or Placebo

A Study of Carotid Artery Intima-Media Thickness Following Exposure to Raloxifene HCl or Placebo

NCT00532246•Eli Lilly and Company

Summary

The purpose of this study is to measure carotid artery IMT at a single visit in a subset of women previously enrolled in the CORE (H3S-MC-GGJY) trial

Eligibility

Age

55 - No limit years

Sex

FEMALE

Healthy Volunteers

Inclusion Criteria

•Patients must have completed the Eli Lilly and Company clinical trial CORE (H3S-MC-GGJY) inclusive of visit 5, in one of the 9 participating study sites in California.
•Patients must have been dispensed study drug in the CORE trial (H3S-MC-GGJY).

Exclusion Criteria

•Have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry
•Have previously withdrawn from this exploratory study or any other study investigating raloxifene
•Are employed by Eli Lilly and Company (that is, employees, temporary contract workers, or designees responsible for the conduct the study). Immediate family of Eli Lilly and Company employees may participate in Lilly-sponsored clinical trials, but are not permitted to participate at an Eli Lilly and Company facility. Immediate family is defined as a spouse, parent, child, or sibling, whether biological or legally adopted
•Are investigator site personnel directly affiliated with the study, or are immediate family of investigator site personnel directly affiliated with the study. Immediate family is defined as a spouse, parent, child, or sibling, whether biological or legally adopted

Locations (5)

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

La Jolla, California, United States

Menlo Park, California, United States

Oakland, California, United States

San Diego, California, United States

Walnut Creek, California, United States

Key Dates

Start Date

March 1, 2003

Completion Date

August 1, 2003

Last Updated

September 20, 2007

Enrollment

147

ACTUAL participants

Conditions

Osteoporosis, Post-Menopausal

Interventions

raloxifene

DRUG

Placebo

DRUG

Romosozumab Effects on Bone Density, Muscle Mass, and Spine Surgery Outcomes

NCT06973109

Osteoporosis, Post-menopausal

View study

COMPLETEDPHASE3

PTH Comparison in Post Menopausal Women

NCT00543218

Osteoporosis, Post-Menopausal

View study

COMPLETEDPHASE3

Study of Teriparatide in the Treatment of Postmenopausal Women With Osteoporosis

NCT00532207

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 20, 2007Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions